This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Martha Stewart's Rough Trade

This is the story of how Martha Stewart saved $50,000 and lost $166 million trading stocks.

Earlier this month, Sam Waksal, the former chief executive officer of biotech company ImClone (IMCL), was arrested in his Soho loft and charged with insider trading. On Dec. 27, 2001, it is alleged, Waksal got wind that the Food and Drug Administration would on the next day announce its rejection of ImClone's application for its anticancer drug Erbutix. Waksal is charged with giving a heads-up to family members and other associates, who then proceeded to dump hundreds of thousands of shares on Dec. 27 and Dec. 28, saving millions of dollars when the stock fell nearly 20% on Dec. 31.

How does the domestic doyenne figure in all this? On Dec. 27, Stewart, whose daughter once dated Sam Waksal, sold her entire 3,928-share Imclone position at $58 per share. By selling ahead of the bad news, Stewart saved $49,532.

But the trade has cost her far more -- her stock in her own company lost nearly $166 million in value, and her reputation suffered incalculable damage.

Regulators are now investigating Stewart's stock trades, and Stewart has categorically denied any wrongdoing. But as a professional decorator and caterer like Stewart knows, appearance and taste matter almost as much as substance. And while circumstantial, the evidence trickling out makes Stewart's denials about as tough to swallow as a brisket that has been braised for just 30 minutes instead of the requisite three hours.

When news of her sale was first reported in early June, Stewart said it was triggered by a stop-limit order she had placed with her Merrill Lynch broker, Peter Bacanovic. In this case, said Stewart, the order was set at $60. And on Dec. 27, the stock did indeed fall below $60 for the first time in several weeks. Innocent enough.

There's only one problem: Merrill apparently has no written or digital record of the stop order. And according to The Wall Street Journal, Bacanovic's assistant, Douglas Faneuil, has provided information suggesting that none ever existed.

Now, it's hard to believe that someone so famously meticulous -- OK, anal -- would place a stop-order on a stock and not get the routine documentation. (If I place one on my Fidelity account, I receive printed confirmation in the mail within three days.) And Stewart, who once worked as a stockbroker, is no financial naif.

Besides, if she was just a passive investor in ImClone -- and not an active trader -- why did she allegedly call Sam Waksal on the afternoon of Dec. 27 seeking information?

More circumstantial evidence: Stewart's broker is a former ImClone executive and counted Sam Waksal and Waksal's daughter among his clients. Phone records show Bacanovic and Stewart talked on Dec. 27, right before her shares were sold. Investigators are looking into whether Bacanovic sold the Waksal shares on Dec. 27 and Dec. 28. Bacanovic has been placed on leave by Merrill, for "factual issues regarding a client transaction." This is not a good thing.

Is Stewart guilty of insider trading? Probably not. My theory: Bacanovic got the information from someone connected to ImClone, probably Waksal, and blew out the ImClone positions held by all his clients, including Stewart.

But Stewart is certainly guilty of other offenses. How could someone as savvy as Stewart not realize that trading ImClone stock on material nonpublic information, through a broker who also manages money for ImClone insiders, and then saying publicly that there was a stop order when there was no documentation to back up the assertion, would reek as much as a six-day-old unrefrigerated salmon mousse? Even more significant, how could she not realize that a disclosure that even hints of wrongdoing -- especially in this environment -- would cause lasting damage to her company?

Martha Stewart Living Personified

More than perhaps any large company (2001 revenue: $295 million), the value of Stewart's eerily named conglomerate Martha Stewart Living Omnimedia (MSO - Get Report) hinges upon the image of its leader. Sure, it has cash-generating assets, like a magazine, and licenses with retailers like Kmart. But MSO's real asset is Stewart's aura of wholesome domesticity, faux as it is.

In a very real sense, the company's stock price represents the value the public places on Martha Stewart and everything she stands for -- quite apart from the fundamentals. Tyco's (TYC) shares took a hit when CEO Dennis Kozlowski was indicted for tax evasion. But the company's customers won't stop buying pumps or home security systems because of it. Not so with Stewart and her merchandise. It's doubtful, for example, that CBS would continue to book her on The Early Show after viewers have seen her doing a perp walk on the network's air.

And that's why investors have pummeled Martha Stewart Living's shares since her name became publicly identified with the brewing ImClone scandal on June 6. Monday, they fell to an all-time low of $12.55, down 34% from the June 6 price. This, even as the company reaffirmed that its financial performance would meet or exceed expectations. Even though the stock rebounded by a buck Tuesday, Stewart's personal stake -- 30.7 million shares as of last April, representing 62% of the company -- has lost $166 million in value.

On Wall Street, there's short-term greedy and long-term greedy. Throughout her career, Stewart had generally been long-term greedy. She built up a company over two decades, steadily expanded it into new media, and sold shares to the public at the height of the market, all while maintaining ironclad control. At its height, Stewart's stake was worth more than half a billion dollars.

When it came to ImClone -- whether she was guilty of trading on insider information or not -- Stewart was plainly short-term greedy. Why was a woman worth $500 million spending her valuable time tracking the action in a stock position worth a piddling $240,000? It's clear now that Stewart -- whether the stop-limit order was phantom or real -- made a decision on a short-term investment without considering how it might affect her most valuable asset, one worth 2,375 times more than her ImClone position.

Even before the investigations cropped up, ImClone was a controversial company. Her broker had worked at the company, and Stewart had been publicly identified as a social associate of Waksal.

If she did have the information and chose to preserve a few bucks by bailing on Dec. 27, then Stewart is guilty of more than insider trading, she's guilty of stupidity. And if, as she asserts, the trade was the result of an innocent limit order, and she kept quiet about it for six months while other details leaked out, then she's guilty of poor image management. Which, as far as the stock of Martha Stewart Living Omnimedia is concerned, may be the more devastating charge.

Either way, it's a very bad thing.
Daniel Gross is a frequent contributor to RealMoney and the author of Bull Run: Wall Street, the Democrats, and the New Politics of Personal Finance . At the time of publication, Gross had no positions in any securities mentioned in this column, although holdings can change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. He welcomes your feedback . has a revenue-sharing relationship with under which it receives a portion of the revenue from Amazon purchases by customers directed there from

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $1.18 -1.67%
MSO $6.07 -0.65%
AAPL $118.30 0.42%
FB $104.24 -1.15%
GOOG $742.60 -1.02%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs